Fda S Mrd Draft Guidance

Media Summary: On September 9, 2022, the U.S. Food and Drug Administration ( In this week's , myeloma expert Dr. Brian G.M. Durie answers the question: What does the In this portion of the webinar, I will discuss

Fda S Mrd Draft Guidance - Detailed Analysis & Overview

On September 9, 2022, the U.S. Food and Drug Administration ( In this week's , myeloma expert Dr. Brian G.M. Durie answers the question: What does the In this portion of the webinar, I will discuss Learn about distinctions between surrogate and survival end points, key elements of the Iris P. Masucci from CDER's Office of Medical Policy discusses Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, and Heinz Ludwig, MD, of the Wilhelminen ...

In this week's video, Dr. Durie discusses the two main types of minimal residual disease ( This presentation reviewed the comparative analyses (CA) process and provided key principles for conducting effective ... This inaugural webinar was a collaborative effort between

Photo Gallery

FDA’s MRD Draft Guidance: Faster Myeloma Drug Approvals Through Molecular Endpoints

Public Webinar: Patient-Focused Drug Development Draft Guidance 3

Minimal Residual Disease and Complete Response in Multiple Myeloma - FDA Draft Guidance Explained

Updated FDA MRD guidelines for hematological malignancies

Public Webinar: Patient-Focused Drug Development Draft Guidance 4

What does the FDA approval of MRD testing for myeloma mean for patients and drug development?

FDA’s Dosage and Administration Section of Labeling Draft Guidance Day 1

Draft Guidance #254: Donor Eligibility for ACTPs

FDA guidance and standards – Do you need help finding what’s new for 2026 quickly?

The Future of FDA Guidance and Accelerated Approvals in Oncology With Drs. Hadfield and Singh

Writing the “Indications and Usage” Section of Labeling: FDA’s New Draft Guidance – Sep. 27, 2018

Digital Health Technologies (DHTs) for Remote Data Acquisition Draft Guidance

View Detailed Profile

FDA’s MRD Draft Guidance: Faster Myeloma Drug Approvals Through Molecular Endpoints

FDA’s MRD Draft Guidance: Faster Myeloma Drug Approvals Through Molecular Endpoints

The

Public Webinar: Patient-Focused Drug Development Draft Guidance 3

Public Webinar: Patient-Focused Drug Development Draft Guidance 3

On September 9, 2022, the U.S. Food and Drug Administration (

Minimal Residual Disease and Complete Response in Multiple Myeloma - FDA Draft Guidance Explained

Minimal Residual Disease and Complete Response in Multiple Myeloma - FDA Draft Guidance Explained

In this video, we break down

Updated FDA MRD guidelines for hematological malignancies

Updated FDA MRD guidelines for hematological malignancies

Nicole Gormley, MD,

Public Webinar: Patient-Focused Drug Development Draft Guidance 4

Public Webinar: Patient-Focused Drug Development Draft Guidance 4

On May 4, 2023, the

What does the FDA approval of MRD testing for myeloma mean for patients and drug development?

What does the FDA approval of MRD testing for myeloma mean for patients and drug development?

In this week's #AskDrDurie, myeloma expert Dr. Brian G.M. Durie answers the question: What does the

FDA’s Dosage and Administration Section of Labeling Draft Guidance Day 1

FDA’s Dosage and Administration Section of Labeling Draft Guidance Day 1

In this video,

Draft Guidance #254: Donor Eligibility for ACTPs

Draft Guidance #254: Donor Eligibility for ACTPs

In this portion of the webinar, I will discuss

FDA guidance and standards – Do you need help finding what’s new for 2026 quickly?

FDA guidance and standards – Do you need help finding what’s new for 2026 quickly?

Do you feel like new

The Future of FDA Guidance and Accelerated Approvals in Oncology With Drs. Hadfield and Singh

The Future of FDA Guidance and Accelerated Approvals in Oncology With Drs. Hadfield and Singh

Learn about distinctions between surrogate and survival end points, key elements of the

Writing the “Indications and Usage” Section of Labeling: FDA’s New Draft Guidance – Sep. 27, 2018

Writing the “Indications and Usage” Section of Labeling: FDA’s New Draft Guidance – Sep. 27, 2018

Iris P. Masucci from CDER's Office of Medical Policy discusses

Digital Health Technologies (DHTs) for Remote Data Acquisition Draft Guidance

Digital Health Technologies (DHTs) for Remote Data Acquisition Draft Guidance

FDA

MRD in myeloma: the FDA perspective

MRD in myeloma: the FDA perspective

Hermann Einsele, MD, FRCP, of the University of Würzburg, Würzburg, Germany, and Heinz Ludwig, MD, of the Wilhelminen ...

How does the FDA approval of NGS to test for MRD in multiple myeloma affect patients?

How does the FDA approval of NGS to test for MRD in multiple myeloma affect patients?

In this week's video, Dr. Durie discusses the two main types of minimal residual disease (

FDA’s Dosage and Administration Section of Labeling Draft Guidance Day 2

FDA’s Dosage and Administration Section of Labeling Draft Guidance Day 2

In this video,

FDA-NIH 2024 | D1S05 - Overview of CDER Nonclinical Resources and Guidance for Approaching First...

FDA-NIH 2024 | D1S05 - Overview of CDER Nonclinical Resources and Guidance for Approaching First...

This presentation provided comprehensive

GDF 2024 | D2S03-2 - Comparative Analyses Update

GDF 2024 | D2S03-2 - Comparative Analyses Update

This presentation reviewed the comparative analyses (CA) process and provided key principles for conducting effective ...

FDA | NIH: Regulatory Do’s and Don'ts: Tips from FDA – CDER Segment

FDA | NIH: Regulatory Do’s and Don'ts: Tips from FDA – CDER Segment

This inaugural webinar was a collaborative effort between

CDER & CBER All Hands: Implementing the FDA's Plausible Mechanism Framework

CDER & CBER All Hands: Implementing the FDA's Plausible Mechanism Framework

To discuss the plausible mechanism

Related Video Content

U.S. Food and Drug Administration information

Apr 29, 2026 · The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security...

Food and Drug Administration (FDA) | USAGov information

The Food and Drug Administration (FDA) is responsible for protecting the public health by assuring the safety,...

Food and Drug Administration - Wikipedia information

The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human...

What does the Food and Drug Administration (FDA) do? - USAFacts information

The Food and Drug Administration (FDA) is a subdivision of the US Department of Health and Human Services responsible...

Food and Drug Administration | Description, History, Activities ... information

May 22, 2026 · Food and Drug Administration (FDA), agency of the U.S. federal government authorized by Congress to...